I personally have no capacity. From the last investor call, CR shouldn’t be required for at least another year. This will allow for some readouts that’ll hint at efficacy before needing to press the CR button.
Would be gutted if they won’t able to find a partner - or decide to raise before the imminent (2Q quarter Apr-June) announcements which will set us up for a share price/CR that’ll be higher than the last one (17c+):
Clinical program:
1) VP-001 HREC approval/first patient recruited/dosed - ETA April 2023
Announced Pre-clinical programs:
1) ADOA lead selection and pre-clinical data/IND roadmap 2) Platform technology upgrade - v2/next generation PPMO that is multifactor improvement to efficacy/safety - I believe this will tie in with ADOA lead incorporating/showcasing this v2 delivery 3) PMS pre-clinical updates
Secret pre-clinical programs:
3) shunning the light on other programs - 3 disease targets will be selected for the next wave (each wave will have 3, from which 1 will enter IND per year) they have about 9 other programs currently on the go
PYC Price at posting:
7.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)